Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.38 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.38 |
| ▸ | F2R | P25116 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2525770 | 0.88 | KMT2A (0.43) | AOC3MEN1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL2529693 | 0.87 | AOC3 (0.41) | AOC3MEN1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL2532624 | 0.87 | TAAR1 (0.39) | AOC3MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL2528584 | 0.86 | MEN1 (0.45) | AOC3MEN1KMT2AMAPT | |
| SCHEMBL2526417 | 0.86 | KMT2A (0.46) | AOC3MEN1KMT2AUTS2RMAPT | |
| SCHEMBL5360820 | 0.86 | AOC3 (0.53) | AOC3 | |
| SCHEMBL5361268 | 0.86 | AOC3 (0.53) | AOC3 | |
| SCHEMBL1979471 | 0.86 | MEN1 (0.43) | AOC3MEN1KMT2ASMN1; SMN2CYP1A2 | |
| SCHEMBL5350824 | 0.86 | AOC3 (0.53) | AOC3 | |
| SCHEMBL3722932 | 0.85 | AOC3 (0.50) | AOC3MEN1KMT2ASMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090029999-A1 | Synephrine derivatives useful as anti-inflammatory agents | UNIVERSITEIT GENT (BE) | 2009-01-29 | — | — | US | disclosed |
| WO-2006136823-A1 | HETEROCYCLIC CONTAINING AMINES AS KINASE B INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029999-A1 | Synephrine derivatives useful as anti-inflammatory agents | HRH1, HRH3, HRH2 | AOC3 2105/4885MEN1 1126/4885KMT2A 2317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.